Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer
13 Jul 2023
bởiElaine Soliven
Treatment with mirvetuximab soravtansine, an antibody-drug conjugate (ADC) targeting folate receptor-alpha (FRα), led to significantly better survival outcomes in women with platinum-resistant ovarian cancer (PROC) compared with the investigator’s choice of chemotherapy, according to the MIRASOL trial presented at ASCO 2023.